bioRxiv · 10.1101/2025.04.09.648026
Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model
Abstract
-synuclein (SNCA) is the greatest genetic risk factor for sporadic Parkinsons Disease (PD). Misfolding and overexpression of SNCA underlie pathognomonic features of PD, including SNCA aggregates and midbrain dopaminergic (mbDA) neurodegeneration. We recently identified an SNCA intronic sequence that harbors variation associated with PD risk and demonstrated its role as a neuronal cis-regulatory element (CRE). Here, we engineered a mouse model lacking this sequence, which exhibits significantly reduced Snca transcription in mbDA neurons. Employing a battery of motor, molecular, and histological assays in an established mouse model of PD, we demonstrate that mice lacking this Snca enhancer are protected against PD-relevant histopathology and motor impairments. By targeting a cell-dependent CRE to diminish PD onset/progression in mice, we introduce a potentially powerful therapeutic avenue for PD.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Boyd, R. J., Kho, A. R., McClymont, S., Loftus, S. K., Ko, H., McCallion, A. S.. 2025-04-15. Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model. https://doi.org/10.1101/2025.04.09.648026
Cite the original work for its findings. Save a collection to share your selection of sources.